The global rise in cancer incidence, the known carcinogenic influence of environmental estrogens, their abundance in economically developed countries, and the prominent role that GPER plays in metabolic syndrome, a cancer-promoting health condition, are additional reasons for developing GPER-targeted cancer therapeutics. This evidence concerns the gene GPER1 and metabolic syndrome.